Want to see HK:0108 full AI Analyst Report?
GR Properties Limited (0108) AI Stock Analysis
GR Properties Limited
(HKEX:0108)
The score is held back primarily by weak and volatile profitability (net losses in four of the last five years and a -33% net margin in 2025) and higher leverage (debt-to-equity ~1.38). Offsetting this, operating and free cash flow improved materially in 2025. Technical signals are mixed but generally soft (price below 20-day and 200-day averages, RSI below 50), and valuation is constrained by a negative P/E with no dividend yield provided.
GR Properties Limited (0108) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 7.06B
- Dividend Yield
- ―
- Average Volume (3M)
- 998.92K
- Price to Earnings (P/E)
- -37.6
- Beta (1Y)
- -0.16
- Revenue Growth
- 24.51%
- EPS Growth
- 80.28%
- Country
- Hong Kong
- Employees
- 428
- Sector
- Real Estate
- Sector Strength
- 65
- Industry
- Real Estate - Services
GR Properties Limited Business Overview & Revenue Model
Company Description
An investment holding company principally engaged in property-related businesses. The company operates through two segments: Property Development and Investment, and Property Management, which provides services for office buildings, residential prope...
How the Company Makes Money
null
GR Properties Limited Financial Statement Overview
Summary
Cash generation is improving with positive operating cash flow in 2023–2025 and solid 2025 free cash flow (~75M) with strong growth (+63%). However, profitability remains weak and volatile, with net losses in four of the last five years and a sharply negative 2025 net margin (-33%). Balance-sheet risk increased as total debt rose in 2025, lifting debt-to-equity to ~1.38 and reducing financial flexibility.
Income Statement
36NegativeBalance Sheet
46NeutralCash Flow
58Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 404.24M | 348.91M | 310.02M | 352.64M | 352.28M | 331.33M |
| Gross Profit | 397.35M | 347.44M | 220.08M | 275.88M | 279.56M | 250.04M |
| EBITDA | 27.19M | 18.88M | -840.68M | 61.70M | -194.62M | 245.17M |
| Net Income | -182.33M | -109.63M | -918.50M | -129.31M | -320.13M | 207.63M |
Balance Sheet | ||||||
| Total Assets | 6.26B | 5.74B | 5.42B | 6.41B | 6.24B | 6.89B |
| Cash, Cash Equivalents and Short-Term Investments | 231.06M | 312.76M | 311.31M | 316.82M | 365.00M | 304.05M |
| Total Debt | 4.04B | 2.89B | 1.91B | 2.70B | 2.39B | 2.17B |
| Total Liabilities | 5.17B | 4.80B | 3.29B | 3.31B | 2.99B | 3.03B |
| Stockholders Equity | 1.02B | 936.36M | 2.13B | 3.10B | 3.25B | 3.86B |
Cash Flow | ||||||
| Free Cash Flow | 103.04M | 75.38M | 79.13M | 103.25M | -179.96M | -32.50M |
| Operating Cash Flow | 147.57M | 121.78M | 80.28M | 104.22M | -179.04M | -31.63M |
| Investing Cash Flow | -56.67M | -214.24M | 7.95M | -327.49M | -136.66M | 64.19M |
| Financing Cash Flow | 34.97M | 14.28M | -199.13M | 173.70M | 351.88M | -43.75M |
GR Properties Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0108, the sentiment is Negative. The current price of 2.13 is below the 20-day moving average (MA) of 2.48, below the 50-day MA of 2.15, and below the 200-day MA of 2.32, indicating a bearish trend. The MACD of 0.07 indicates Positive momentum. The RSI at 42.23 is Neutral, neither overbought nor oversold. The STOCH value of 23.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0108.
GR Properties Limited Peers Comparison
Overall Rating
HK:266974Outperform
HK:007171Outperform
HK:010156Neutral
HK:022555Neutral
HK:199751Neutral- HK:010846Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2669 | 74Outperform | HKD 10.57B | 7.32 | 21.17% | 9.32% | 10.76% | -12.76% |
| HK:0071 | 71Outperform | HKD 6.77B | 9.89 | 3.22% | 5.41% | -10.82% | -1.24% |
| Sector * | 65Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% |
| HK:0101 | 56Neutral | HKD 32.21B | 18.76 | 1.21% | 8.39% | 9.89% | -22.12% |
| HK:0225 | 55Neutral | HKD 558.61M | -13.70 | -0.94% | 7.10% | -0.96% | 91.94% |
| HK:1997 | 51Neutral | HKD 94.67B | -46.68 | -1.12% | 5.13% | -0.55% | -337.48% |
| HK:0108 | 46Neutral | HKD 7.06B | -37.61 | -18.68% | ― | 24.51% | 80.28% |
* Real Estate Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0108 | GR Properties Limited | 2.13 | 0.18 | 8.97% | |
| HK:2669 | China Overseas Property Holdings | 3.22 | -1.36 | -29.74% | |
| HK:0101 | Hang Lung Properties | 6.19 | -1.91 | -23.54% | |
| HK:0071 | Miramar Hotel & Investment Co | 9.79 | 0.60 | 6.56% | |
| HK:1997 | Wharf Real Estate Investment Co | 31.18 | 9.79 | 45.76% | |
| HK:0225 | Pokfulam Development Co. Ltd. | 5.07 | -0.45 | -8.20% |
GR Properties Limited Corporate Events
SR Medical Technology Appoints Veteran Engineer Shao Jiyou as Executive Director
SR Medical Technology Company Limited has appointed Mr. Shao Jiyou as an executive director, effective 16 September 2026. Shao, a professor-level senior engineer with extensive construction and corporate management experience and chairman of BCEG Roa...
SR Medical Technology Details Board and Committee Structure
SR Medical Technology Company Limited has outlined the current composition of its board, comprising six executive directors and three independent non-executive directors. The disclosure underscores the mix of management and independent oversight at t...
SR Medical Technology Swings to Interim Loss Despite Double‑Digit Revenue Growth
SR Medical Technology Company Limited reported a strong top‑line performance for the six months ended 30 June 2026, with revenue rising 30.7% year on year to approximately HK$223.1 million. The increase reflects expansion in its medical technol...
SR Medical Technology flags sharp interim loss after cost surge
SR Medical Technology Company Limited has warned that it expects to post a loss attributable to shareholders of between HK$68 million and HK$73 million for the six months ended 30 June 2026, compared with a profit of about HK$2.1 million a year earli...
SR Medical Technology Sets Board Meeting to Approve Interim Results and Consider Dividend
SR Medical Technology Company Limited has scheduled a board meeting for 31 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider whether to declare, recommend or pay a dividend, a de...
SR Medical Technology names seasoned finance executive as new CFO
SR Medical Technology Company Limited announced that chief financial officer Li Chenji will resign effective 13 August 2026 due to other business commitments, with the board noting there is no disagreement and no issues requiring shareholder attentio...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026